Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New syrup shows promise for soothing stubborn heartburn

NCT ID NCT07563790

Symptom relief Sponsor: Rose Pharma SA Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new syrup, called Fibroin Syrup, to see if it is safe and can help reduce symptoms of gastroesophageal reflux disease (GERD), like heartburn and regurgitation. The study included 47 adults with non-erosive reflux disease (NERD) who had symptoms for at least 8 weeks. Participants took the syrup after each main meal for 6 weeks. The goal was to check for side effects and see if symptoms improved.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

47 people

The number who actually took part.

Started

Jul 2024

Finished

Aug 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Patient who signed Informed consent form; * Male or Female over 18 years old at the time of the signature of the Informed consent form; * Symptomatic non-erosive reflux disease (heartburn and/or regurgitation) for at least 8 weeks; * RDQ (Reflux Disease Questionnaire) score ≥ 12 at baseline (questionnaire specific for reporting the frequency and severity of upper gastrointestinal symptoms); * Willingness to follow all study procedures, including attending all site visits, tests and examinations. Exclusion Criteria: * Esophagitis according to the Los Angeles classification (grade A to D); * Diagnosis of Helicobacter pylori infection; * Use of proton pump inhibitors or H2 receptor antagonists in the previous 4 weeks; * Uncontrolled cardiac, renal, liver or pulmonary disease; * Diabetes; * Active malignant neoplasia; * Pregnancy or breast-feeding; * Known allergy to device components; * Simultaneous participation in an interventional study or participation in an interventional study in the last 1 month before study inclusion; * Known drug and/or alcohol abuse; * Mental incapacity that precludes adequate understanding or cooperation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gastroesophageal reflux (GERD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

dyspepsia gastroesophageal reflux disease Heartburn

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gastroesophageal reflux (GERD) GERD (heartburn, regurgitation, and dyspepsia)

Contacts and locations

Locations

  • UOC Medicina Interna Cardiovascolare - Centro Endoscopia Digestiva - Policlinico di Sant'Orsola - Bologna

    Bologna, BO, 40121, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.